The Investor
30 Sep 2026, 18:06
Eli Lilly’s EloraTZP Delivers Greater Weight Loss Than Tirzepatide in Phase 2b Study
Eli Lilly reported positive Phase 2b results for EloraTZP, an investigational combination of eloralintide and tirzepatide, in adults with obesity or overweight and type 2 diabetes.
At 48 weeks, participants receiving the highest-dose EloraTZP regimen lost an average of 54.1 pounds, or 23.3% of body weight, compared with 34.4 pounds, or 14.8%, for tirzepatide 15 mg alone. The combination also reduced A1C by up to 2.9 percentage points versus 2.4 points with tirzepatide.
EloraTZP combines eloralintide, a selective amylin receptor agonist, with tirzepatide, which targets GIP and GLP-1 receptors. Lilly is aiming to simultaneously engage three metabolic pathways involved in appetite and glucose regulation.
The study enrolled 367 adults and met its primary and secondary endpoints. The most common adverse events were gastrointestinal and were generally mild or moderate, although discontinuation rates due to adverse events were higher in some EloraTZP combination groups.
Lilly said it plans to begin Phase 3 trials of a co-formulated EloraTZP product in the fourth quarter of 2026.
The results strengthen Lilly’s obesity and diabetes pipeline by suggesting that adding an amylin-based mechanism to tirzepatide could deliver additional weight loss and glucose control beyond tirzepatide alone.
Eli Lilly reported positive Phase 2b results for EloraTZP, an investigational combination of eloralintide and tirzepatide, in adults with obesity or overweight and type 2 diabetes.
At 48 weeks, participants receiving the highest-dose EloraTZP regimen lost an average of 54.1 pounds, or 23.3% of body weight, compared with 34.4 pounds, or 14.8%, for tirzepatide 15 mg alone. The combination also reduced A1C by up to 2.9 percentage points versus 2.4 points with tirzepatide.
EloraTZP combines eloralintide, a selective amylin receptor agonist, with tirzepatide, which targets GIP and GLP-1 receptors. Lilly is aiming to simultaneously engage three metabolic pathways involved in appetite and glucose regulation.
The study enrolled 367 adults and met its primary and secondary endpoints. The most common adverse events were gastrointestinal and were generally mild or moderate, although discontinuation rates due to adverse events were higher in some EloraTZP combination groups.
Lilly said it plans to begin Phase 3 trials of a co-formulated EloraTZP product in the fourth quarter of 2026.
The results strengthen Lilly’s obesity and diabetes pipeline by suggesting that adding an amylin-based mechanism to tirzepatide could deliver additional weight loss and glucose control beyond tirzepatide alone.
